Analysts are saying that Becton Dickinson could fall by 2030. Bullish on BDX? Invest in Becton Dickinson on SoFi with no commissions. If it’s your first time signing up for SoFi, you’ll receive up to $1,000 in stock when you first fund your account. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025.
Becton, Dickinson, and Co. (BDX) is a long-time industry leader with predictable cash flow, a strong pipeline and solid demand for its medical technology products. However, potential cuts in federal funding and integration risks with a recent partial spinoff are notable.
In this article, we’ll look at BDX’s latest share price, Wall Street sentiment, multiyear price forecasts, and the key factors that are playing a critical role in the company’s path going forward.
Current Stock Overview
Market Cap: $56.03 billion
Trailing P/E Ratio: 33.11
Forward P/E Ratio: 12.89
1-Year Return: -13%
2025 YTD: -14%
BDX has a consensus Buy rating from 18 analysts, according to Benzinga. The average price target is $247.56 per share. The highest price target is $304, and the lowest is $184. The three most recent ratings suggest a near-term average target of $201.
Quick Snapshot Table of Predictions & Methodology for Forecasting
Year | Bullish Prediction | Average Prediction | Bearish Prediction |
|---|---|---|---|
2025 | $203.3 | $197.05 | $191.24 |
2026 | $226.45 | $204.91 | $180.96 |
2027 | $234.55 | $209.26 | $190.52 |
2028 | $203.39 | $193.86 | $182.19 |
2029 | $205.48 | $163.15 | $136.38 |
2030 | $188.61 | $170.7 | $150.66 |
2031 | $195.37 | $174.23 | $158.64 |
2032 | $169.38 | $161.36 | $151.69 |
2033 | $171.12 | $135.71 | $113.47 |
2040 | $117.35 | $111.72 | $105.09 |
2050 | $75.35 | $68.28 | $60.19 |
The forecast range in this table is based on algorithmic projections provided by CoinCodex. These models use historical price trends, volatility patterns, and moving averages to estimate future stock prices over multiple time horizons.
Bull & Bear Case
Becton Dickinson is an industry leader with long-term patents for key products, but federal funding cuts can hurt its life science business.
Bull Case
- A vast pipeline puts Becton Dickinson on track to launch 100 new products per year.
- Consumables and instrument replacement cycles generate recurring revenue, which makes cash flow more predictable.
- Most of Becton Dickinson’s customers are hospitals and clinics, which suggests a steady demand for products from a company that’s been in business for more than 125 years.
Bear Case
- Cuts in federal funding can hurt research customers that depend on federal U.S. grants to buy Becton Dickinson’s capital-intensive life science products, which make up more than 20% of total revenue.
- BDX’s partial sale of its Biosciences & Diagnostic Solutions business to life science company Waters Corporation isn’t guaranteed to be a tax-free event and also comes with integration risk.
- Increased industry consolidation gives hospitals more pricing poji0wer over Becton Dickinson and its competitors, which can tighten profit margins.
Stock Price Prediction for 2025
CoinCodex projects a high probability of BDX gaining value for the rest of the year. A vast pipeline of products and reliable revenue from hospitals and clinics may elevate the stock.
Stock Price Prediction for 2026
CoinCodex projects BDX stock losing value in 2026, but the highest price target suggests that shares may appreciate. Any federal funding cuts or issues with the Waters Corporation merger can result in the lower end of the forecast coming true.
Stock Price Prediction for 2030
CoinCodex projects BDX stock dropping in 2030. Federal funding cuts and a lack of innovative products leading up to patent expirations can result in the price going down.
Investment Considerations
Becton Dickinson has a vast product pipeline and seven years before its key patents start to expire. Recurring revenue provides notable stability, but any cuts in federal funding and integration issues can create headwinds for the stock. The mergers and consolidations of hospitals can tighten margins.
The company has been in business for over 125 years, indicating durability that may be attractive to income investors who value its stock’s 2.18% dividend yield.
About Marc Guberti
Marc Guberti is an investing writer passionate about helping people learn more about money management, investing and finance. He has more than 10 years of writing experience focused on finance and digital marketing. His work has been published in U.S. News & World Report, USA Today, InvestorPlace and other publications.
